BIOMAT Database Logo BIOMAT Database Logo

Clinical pharmacology of 2',3'-dideoxyinosine in human immunodeficiency virus-infected children. 1992

F M Balis, and P A Pizzo, and K M Butler, and M E Hawkins, and P Brouwers, and R N Husson, and F Jacobsen, and S M Blaney, and J Gress, and P Jarosinski
Pediatric Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892.

The pharmacokinetics of intravenous and oral 2',3'-dideoxyinosine (ddI) and the relationships between pharmacokinetic parameters and measures of response were studied in 48 human immunodeficiency virus-infected children. Disappearance of ddI from plasma after the intravenous dose was rapid and biexponential, with half-lives of 12 min and 1.0 h and a total clearance of 510 +/- 180 ml/min/m2. After oral administration, ddI absorption was limited and variable (mean bioavailability, 19% +/- 17%). A plasma ddI concentration-response relationship was observed for both decline in viral p24 antigen levels and improvement in intelligence quotient score. A limited sampling model was developed that accurately predicts the area under the ddI plasma concentration-time curve from one to three plasma samples. Although this pharmacokinetic study was done in children, the results also have relevance to adults and suggest that individualization of dose and schedule through therapeutic drug monitoring may be necessary to achieve optimal response.

UI MeSH Term Description Entries
D007223 Infant A child between 1 and 23 months of age. Infants
D007262 Infusions, Intravenous The long-term (minutes to hours) administration of a fluid into the vein through venipuncture, either by letting the fluid flow by gravity or by pumping it. Drip Infusions,Intravenous Drip,Intravenous Infusions,Drip Infusion,Drip, Intravenous,Infusion, Drip,Infusion, Intravenous,Infusions, Drip,Intravenous Infusion
D008297 Male Males
D002648 Child A person 6 to 12 years of age. An individual 2 to 5 years old is CHILD, PRESCHOOL. Children
D002675 Child, Preschool A child between the ages of 2 and 5. Children, Preschool,Preschool Child,Preschool Children
D004341 Drug Evaluation Any process by which toxicity, metabolism, absorption, elimination, preferred route of administration, safe dosage range, etc., for a drug or group of drugs is determined through clinical assessment in humans or veterinary animals. Evaluation Studies, Drug,Drug Evaluation Studies,Drug Evaluation Study,Drug Evaluations,Evaluation Study, Drug,Evaluation, Drug,Evaluations, Drug,Studies, Drug Evaluation,Study, Drug Evaluation
D005260 Female Females
D005500 Follow-Up Studies Studies in which individuals or populations are followed to assess the outcome of exposures, procedures, or effects of a characteristic, e.g., occurrence of disease. Followup Studies,Follow Up Studies,Follow-Up Study,Followup Study,Studies, Follow-Up,Studies, Followup,Study, Follow-Up,Study, Followup
D006207 Half-Life The time it takes for a substance (drug, radioactive nuclide, or other) to lose half of its pharmacologic, physiologic, or radiologic activity. Halflife,Half Life,Half-Lifes,Halflifes
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

F M Balis, and P A Pizzo, and K M Butler, and M E Hawkins, and P Brouwers, and R N Husson, and F Jacobsen, and S M Blaney, and J Gress, and P Jarosinski
Retinal toxicity in human immunodeficiency virus-infected children treated with 2',3'-dideoxyinosine.
January 1992, American journal of ophthalmology,
F M Balis, and P A Pizzo, and K M Butler, and M E Hawkins, and P Brouwers, and R N Husson, and F Jacobsen, and S M Blaney, and J Gress, and P Jarosinski
Dideoxyinosine-induced pancreatitis in human immunodeficiency virus-infected children.
February 1997, Pediatric radiology,
F M Balis, and P A Pizzo, and K M Butler, and M E Hawkins, and P Brouwers, and R N Husson, and F Jacobsen, and S M Blaney, and J Gress, and P Jarosinski
Dideoxyinosine in children with symptomatic human immunodeficiency virus infection.
January 1991, The New England journal of medicine,
F M Balis, and P A Pizzo, and K M Butler, and M E Hawkins, and P Brouwers, and R N Husson, and F Jacobsen, and S M Blaney, and J Gress, and P Jarosinski
Synergistic anti-human immunodeficiency virus type 1 effect of hydroxamate compounds with 2',3'-dideoxyinosine in infected resting human lymphocytes.
November 1994, Proceedings of the National Academy of Sciences of the United States of America,
F M Balis, and P A Pizzo, and K M Butler, and M E Hawkins, and P Brouwers, and R N Husson, and F Jacobsen, and S M Blaney, and J Gress, and P Jarosinski
Mechanism of resistance of human immunodeficiency virus type 1 to 2',3'-dideoxyinosine.
July 1993, Proceedings of the National Academy of Sciences of the United States of America,
F M Balis, and P A Pizzo, and K M Butler, and M E Hawkins, and P Brouwers, and R N Husson, and F Jacobsen, and S M Blaney, and J Gress, and P Jarosinski
Pharmacokinetics of 2',3'-dideoxyadenosine and 2',3'-dideoxyinosine in patients with severe human immunodeficiency virus infection.
May 1990, Clinical pharmacology and therapeutics,
F M Balis, and P A Pizzo, and K M Butler, and M E Hawkins, and P Brouwers, and R N Husson, and F Jacobsen, and S M Blaney, and J Gress, and P Jarosinski
Determination of ddATP levels in human immunodeficiency virus-infected patients treated with dideoxyinosine.
February 2004, Antimicrobial agents and chemotherapy,
F M Balis, and P A Pizzo, and K M Butler, and M E Hawkins, and P Brouwers, and R N Husson, and F Jacobsen, and S M Blaney, and J Gress, and P Jarosinski
Pharmacology considerations for antiretroviral therapy in human immunodeficiency virus (HIV)-infected children.
October 2003, Seminars in pediatric infectious diseases,
F M Balis, and P A Pizzo, and K M Butler, and M E Hawkins, and P Brouwers, and R N Husson, and F Jacobsen, and S M Blaney, and J Gress, and P Jarosinski
Effect of fluconazole on pharmacokinetics of 2',3'-dideoxyinosine in persons seropositive for human immunodeficiency virus.
May 1995, Antimicrobial agents and chemotherapy,
F M Balis, and P A Pizzo, and K M Butler, and M E Hawkins, and P Brouwers, and R N Husson, and F Jacobsen, and S M Blaney, and J Gress, and P Jarosinski
In vitro selection of variants of human immunodeficiency virus type 1 resistant to 3'-azido-3'-deoxythymidine and 2',3'-dideoxyinosine.
January 1992, Journal of virology,
Copied contents to your clipboard!